Prostate Cell News Volume 7.27 | Jul 29 2016

TOP STORY

Protein ZMYND8 Tied to Suppression of Prostate Cancer Tumor Metastasis

A protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Molecular Cell] Press Release | Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Investigators describe a novel signaling pathway that couples the αvβ6 integrin cell surface receptor to androgen receptor via activation of JNK1 and causes increased nuclear localization and activity of androgen receptors. [Cancer Res] Abstract

GRM1 Is an Androgen-Regulated Gene and Its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models

Researchers determined the relationship between GRM1 and AR, PSA, and tumor growth, remission, and recurrence in preclinical prostate cancer models. [Clin Cancer Res] Abstract

Delphinidin Induces Apoptosis via Cleaved HDAC3-Mediated p53 Acetylation and Oligomerization in Prostate Cancer Cells

Investigators identified the epigenetic modulators that mediate the apoptotic effect of delphinidin in human prostate cancer cells. [Oncotarget] Full Article

PDHA1 Gene Knockout in Prostate Cancer Cells Results in Metabolic Reprogramming Towards Greater Glutamine Dependence

Scientists demonstrated that pyruvate dehydrogenase E1α gene knockout (PDHA1 KO) resulted in alterations in tumor cell metabolism by rendering the cells with increased expression of glutaminase1 and glutamate dehydrogenase1, leading to an increase in glutamine-dependent cell survival. [Oncotarget] Full Article

Co-Targeting EGFR and Survivin with a Bivalent Aptamer-Dual SiRNA Chimera Effectively Suppresses Prostate Cancer

Researchers developed a novel strategy by engineering an RNA-based aptamer-siRNA chimera, in which a bivalent aptamer specifically binds prostate-specific membrane antigen via an antibody-like structure to promote siRNA internalization in prostate cancer cells, and two siRNAs specific to EGFR and survivin are fused between two aptamers. [Sci Rep] Full Article

MicroRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate Cancer

Scientists investigated the hypothesis that adipose-derived stromal cells have an inhibitory effect on metastatic tumor progression. [Stem Cells Dev] Abstract

Loss of miR-26a-5p Promotes Proliferation, Migration, and Invasion in Prostate Cancer Through Negatively Regulating SERBP1

Scientists demonstrated that the loss of miR-26a-5p promotes proliferation, migration, and invasion through targeting serpine1 messenger RNA binding protein 1 (SERBP1) in prostate cancer (PC), supporting the tumor-suppressing role of miR-26a-5p in PC. [Tumor Biol] Abstract

MiR-34C Disrupts the Stemness of Purified CD133⁺ Prostatic Cancer Stem Cells

Scientists identified that miR-34C was under-expressed in the purified CD133⁺ prostatic cancer stem cells (PCSCs) and enforced introduction of miR-34C attenuated the stemness of CD133⁺ PCSCs. [Urology] Abstract

CLINICAL RESEARCH

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Researchers tested whether a switch maintenance treatment with orteronel, an oral inhibitor of androgen biosynthesis, prolongs disease control in men with metastatic castration-resistant prostate cancer after documented disease stabilization with docetaxel. [Prostate] Abstract

Liquid Biopsy: Ready to Guide Therapy in Advanced Prostate Cancer?

Recent studies on the presence of androgen receptor variants in circulating tumor cells (CTC) have shown that such molecular characterization of CTC provides a potential for identifying patients with resistance to agents that inhibit the androgen signaling axis, such as abiraterone and enzalutamide. New developments in CTC isolation, as well as in-vitro and in-vivo analysis of CTC will further promote the use of CTC as a tool for retrieving molecular information from advanced tumors in order to identify mechanisms of therapy resistance. [BJU Int] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect^® Non-Invasive Test

BioLight Life Sciences Ltd. announced promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect^® technology. [BioLight Life Sciences Ltd.] Press Release (Download)

Tokai Pharmaceuticals Announces Clinical Update

Tokai Pharmaceuticals Inc. announced that it plans to discontinue the ARMOR3-SV clinical trial, the company’s pivotal Phase III study comparing galeterone to enzalutamide in treatment-naïve metastatic castration-resistant prostate cancer patients whose prostate tumors express AR-V7, following the recommendation made by the trial’s independent Data Monitoring Committee. [Tokai Pharmaceuticals Inc.] Press Release

Pan-European Pension Fund for Scientists Leaves the Station

A pan-European pension fund for researchers, called RESAVER, was set up by a consortium of employers to stimulate researcher mobility. [Science] Editorial

Meet Europe’s New Science Advice Brigade

Too many cooks spoil the broth, goes the saying. Could too many advisers spoil the advice? On the contrary, say the seven scientists who front the European Commission’s new Scientific Advice Mechanism, and who collectively replaced the single-headed role of chief scientific adviser last year. [ScienceInsider] Editorial

Major Review Calls Time on Gaming in UK Research Assessment

The UK’s mammoth periodic audit of its research is set for a shake-up that could change the way universities hire academics – and might also encourage scientists to spend more time on public engagement. [Nature News] Editorial

NEW 28^th European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) SYMPOSIUM
November 29-December 2, 2016
Munich, Germany

Visit our events page to see a complete list of events in the prostate cell community.

NEW Assistant/Associate Professor – Genitourinary Cancers (The University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University)

Postdoctoral Fellow – Radiation and Bone Marrow Transplant (City of Hope)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Breast, Prostate and Pancreatic Cancer (MD Anderson Cancer Center)

Postdoctoral Fellow – Epigenetics and Cell Differentiation (Centre National de la Recherche Scientifique)

Associate Editor (PLOS ONE)

Faculty Positions – Cancer Immunology (University of New Mexico Health Science Center)

Postdoctoral Associate – Cancer Research (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Fellow – Cancer Research (University of California – San Francisco)

Postdoctoral Fellow – Signaling and Epigenetic Regulation (Medical University of South Carolina)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.